Portal de Periódicos da CAPES

PHOTODYNAMIC THERAPY OF SUBFOVEAL AND JUXTAFOVEAL CHOROIDAL NEOVASCULARIZATION IN OCULAR HISTOPLASMOSIS SYNDROME

2004; Lippincott Williams & Wilkins; Volume: 24; Issue: 6 Linguagem: Inglês

10.1097/00006982-200412000-00004

1539-2864

Judy C. Liu, H. Culver Boldt, James C. Folk, Karen M. Gehrs,

Retinal and Optic Conditions

In Brief Purpose: To evaluate the safety and effect on visual acuity of photodynamic therapy (PDT) with verteporfin in patients with subfoveal and juxtafoveal choroidal neovascular membranes from ocular histoplasmosis syndrome (OHS). Methods: Retrospective case series. The visual outcome of 11 patients with subfoveal (n = 6) and juxtafoveal (n = 5) choroidal neovascularization treated with PDT was reviewed. At 1 to 3 months of follow-up, retreatment with PDT was performed if angiography showed leakage. Results: Within the subfoveal group, 3 patients (50%) had improved vision (two or more lines better than initial vision), 2 patients (33.3%) had no change in vision (within 1 line), and 1 (16.7%) lost four lines of vision. At last follow-up, 3 patients (50%) had vision between 20/20 and 20/40 compared with only 1 patient (16.6%) at the initial visit. Mean follow-up was 13.7 months. Within the juxtafoveal group, 3 patients (60%) had improved vision, 1 patient (20%) had no change in vision, and 1 patient (20%) lost nine lines of vision. At last follow-up, 3 of 5 patients (60%) had vision between 20/20 and 20/40 compared with 2 patients (40%) at the initial visit. Mean follow-up was 10.2 months. No significant adverse effects were reported. Conclusion: PDT is a safe and promising option for patients with OHS with choroidal neovascularization that is subfoveal or juxtafoveal. In a retrospective case series of patients with choroidal neovascularization from ocular histoplasmosis syndrome, photodynamic therapy was found to be a safe option for the treatment of subfoveal or juxtafoveal lesions. The majority of eyes treated experienced improvement or stabilization of vision.